Merck KGaA Boosts its Late-Stage Pipeline by Licensing Threshold’s Hypoxia-Targeted Cancer Drug
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 2 (Table of Contents)
Published: 20 Feb-2012
DOI: 10.3833/pdr.v2012.i2.1686 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Merck KGaA has gained worldwide co-development and commercialisation rights to Threshold Pharmaceuticals’ sole drug candidate, the small molecule hypoxia-targeted drug TH-302...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS